Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | WNT3A | P56704 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3207824 | 0.85 | POLB (0.59) | RAD52ALDH1A1GAANPSR1KDM4E | |
| SCHEMBL16098263 | 0.85 | ALDH1A1 (0.57) | RAD52ALDH1A1GAANPSR1KDM4E | |
| SCHEMBL16098331 | 0.85 | POLB (0.69) | RAD52ALDH1A1GAANPSR1KDM4E | |
| SCHEMBL4408076 | 0.84 | WNT3A (0.58) | RAD52ALDH1A1GAANPSR1KDM4E | |
| SCHEMBL16097533 | 0.84 | RAD52 (0.80) | RAD52ALDH1A1KDM4EGFERWNT3A | |
| SCHEMBL6819648 | 0.83 | ALDH1A1 (0.77) | RAD52ALDH1A1GAANPSR1KDM4E | |
| SCHEMBL15828695 | 0.82 | L3MBTL1 (0.60) | ALDH1A1GAANPSR1KDM4EWNT3A | |
| SCHEMBL16104992 | 0.81 | L3MBTL1 (0.74) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL4175098 | 0.80 | RAB9A (0.63) | ALDH1A1GAAKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL5506340 | 0.80 | ALDH1A1 (0.57) | RAD52ALDH1A1GAANPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10130633-B2 | Compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-20 | — | — | US | disclosed |
| EP-2976327-B1 | 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharma AG (DE) | 2017-06-21 | — | — | EP | disclosed |
| EP-2976327-B1 | 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharma AG (DE) | 2017-06-21 | — | — | EP | disclosed |
| US-20160263122-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20160263122-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20160263122-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20160052898-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| US-20160052898-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| US-20160052898-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| US-7776869-B2 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776869-B2 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776869-B2 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20060217380-A1 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263122-A1 | NOVEL COMPOUNDS | NAT1, AADAC, CBR3 | RAD52 3100/4885ALDH1A1 264/4885GAA 616/4885 |
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | IRAK3, IRAK1, MAP3K1 | RAD52 2243/4885ALDH1A1 870/4885GAA 2900/4885 |
| US-20160052898-A1 | NOVEL COMPOUNDS | AADAC, NAT1, CCNA1 | RAD52 2602/4885ALDH1A1 325/4885GAA 412/4885 |
| US-10130633-B2 | Compounds | AADAC, NAT1, CBR3 | RAD52 3035/4885ALDH1A1 277/4885GAA 384/4885 |
| US-20060217380-A1 | Heteroaryl-substituted alkyne compounds and method of use | IRAK3, IRAK1, MAP3K1 | RAD52 2243/4885ALDH1A1 870/4885GAA 2900/4885 |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | RAD52 3675/4885ALDH1A1 1563/4885GAA 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.